Closing the loop with SGLT2 inhibitors for CKD management

Closing the loop with SGLT2 inhibitors for CKD management is organized by Springer Healthcare IME.

Description:
With emerging data and new treatment options available, a clear, multidisciplinary approach to treating chronic kidney disease (CKD) patients is required. Nephrologists have an important role to play in both supporting colleagues to identify patients with CKD and ensuring patients are given appropriate treatment to optimize renal protection and slow disease progression.

Watch our Chair Kieran McCafferty (UK) and speakers Adeera Levin (Canada) and Beatriz Fernández-Fernández (Spain) as they discuss the importance of this role and provide practical advice on identifying patients most likely to benefit from SGLT2 inhibitors.

Learning objectives:
After this activity you will be able to:
• Describe the importance of a clear approach to optimize care for CKD patients
• Identify CKD patients who would most benefit from SGLT2 inhibitor therapy
• Debate the nephrologist’s role in the MDT – elevating the importance of addressing CKD and leading synergized and optimized patient care